Brad, living with cold agglutinin disease, Canada
Blood cancers and rare blood disorders account for some of the most challenging diseases to treat, and patients often have limited therapeutic options available to them. Sanofi is committed to significantly improving the health and lives of people with a range of hematologic conditions.
Across these therapeutic areas, Sanofi is focused on a number of diseases where patients need new treatment options, including hemophilia, cold agglutinin disease, acquired thrombotic thrombocytopenic purpura and multiple myeloma.
Sanofi’s Commitment to Hematology
Bill Sibold, Executive Vice President and Head of Sanofi Genzyme, and John Reed, Global Head of Research and Development, share their insights on how Sanofi is drawing on its deep expertise in hematology and robust R&D programs to address numerous hematologic conditions.
Cold Agglutinin Disease
A disease where Sanofi is currently conducting late-stage research is cold agglutinin disease (CAD), a rare and chronic blood disorder that results in the constant and premature destruction of red blood cells by the body’s immune system.
One of Sanofi’s four focus areas in oncology is blood cancer, where it is working hard to bring a potential new treatment option to patients with multiple myeloma, the second most common blood cancer. It also has early-stage research projects in other blood cancers such as leukemia and lymphoma.
Patients with multiple myeloma typically continue to relapse over time, making it a difficult-to-treat and incurable cancer. These patients are in need of new treatment options. Beyond its late-stage research in this disease, Sanofi is also conducting early-stage research that involves a variety of new approaches to treating this disease. These include next generation antibodies that direct the body’s own immune system to attack cancer cells.